医学
安慰剂
偏头痛
临床终点
临床试验
人口
优势比
物理疗法
内科学
慢性偏头痛
置信区间
可能性
安慰剂组
偏头痛
随机对照试验
不利影响
安全概况
人口研究
作者
Shengyuan Yu,Yasuhiko Matsumori,Byung‐Kun Kim,Anna Gryglas‐Dworak,Giorgadze Gvantsa,Patricia Pozo‐Rosich,Mette Krog Josiassen,Kristina Ranc,Anders Ettrup,Aurélia Mittoux,Bjørn Sperling,Takao Takeshima
出处
期刊:Cephalalgia
[SAGE Publishing]
日期:2025-10-01
卷期号:45 (10): 3331024251386095-3331024251386095
被引量:5
标识
DOI:10.1177/03331024251386095
摘要
Aim We aimed to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine in a predominantly Asian population. Methods The multi-regional, randomized, double-blind, placebo-controlled, phase 3 SUNRISE trial randomly assigned adults with chronic migraine to receive eptinezumab 100 mg, 300 mg, or placebo. The primary endpoint was change from baseline in monthly migraine days (MMDs) during Weeks 1–12. Key secondary efficacy endpoints were 50% reduction in MMDs (Weeks 1–12) and 75% reduction in MMDs (Weeks 1–4, Weeks 1–12), and the percentage of participants experiencing migraine on Day 1. Results Overall, 978 participants received treatment, including 621 (63.5%) from Asia. Both eptinezumab doses met the primary and all key secondary efficacy endpoints. The mean change from baseline in MMDs (Weeks 1–12) was −7.2 for eptinezumab 100 mg, −7.5 for eptinezumab 300 mg, and −4.8 for placebo. Between-group differences were −2.4 for eptinezumab 100 mg versus placebo ( p < 0.0001) and −2.7 for eptinezumab 300 mg versus placebo ( p < 0.0001). Both eptinezumab doses also demonstrated an odds ratio of >2 versus placebo for all migraine responder rates ( p < 0.0001), and a lower percentage of participants experiencing migraine on Day 1 versus placebo ( p ≤ 0.01). Safety outcomes were similar across treatment groups. Conclusions Eptinezumab demonstrated statistically significant greater reductions in MMDs compared with placebo, beginning on Day 1 and sustained through Week 12, with a well-tolerated safety profile consistent with prior clinical trials. Trial registration ClinicalTrials.gov (Identifier: NCT04921384); EudraCT (Identifier: 2020-001657-42).
科研通智能强力驱动
Strongly Powered by AbleSci AI